
Liked By
Spread the love. Be the first to like this post!
Recent CMMB News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/11/2023 09:02:47 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/05/2023 09:50:08 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/05/2023 09:02:30 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/03/2023 12:06:21 PM
- Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients • PR Newswire (US) • 01/03/2023 12:00:00 PM
- Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis • PR Newswire (US) • 12/21/2022 12:00:00 PM
- Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy • PR Newswire (US) • 11/30/2022 12:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/18/2022 12:54:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/17/2022 09:57:27 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/16/2022 12:21:40 PM
- Initial Statement of Beneficial Ownership (3) • Edgar (US Regulatory) • 11/15/2022 09:04:26 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/14/2022 09:11:05 PM
- Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update • PR Newswire (US) • 11/11/2022 11:00:00 AM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/10/2022 09:13:07 PM
- Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19 • PR Newswire (US) • 11/09/2022 01:00:00 PM
- Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update • PR Newswire (US) • 11/01/2022 11:00:00 AM
- Chemomab Therapeutics to Present at Upcoming Scientific Conferences • PR Newswire (US) • 10/28/2022 11:00:00 AM
- Securities Registration: Employee Benefit Plan (s-8) • Edgar (US Regulatory) • 08/15/2022 08:07:34 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/12/2022 11:08:54 AM
- Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities • PR Newswire (US) • 08/12/2022 10:00:00 AM
- Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/12/2022 10:00:00 AM
- Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update • PR Newswire (US) • 08/01/2022 11:00:00 AM
- Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis • PR Newswire (US) • 06/27/2022 12:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 06/21/2022 11:01:09 AM
- Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors • PR Newswire (US) • 06/21/2022 11:00:00 AM
XCPCNL Business Services Announces the Incorporation of ChatGPT Creator OpenAI to Enhance its Customer Service Experience Predictor Platform • XCPL • Jan 30, 2023 8:30 AM
1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition • CBDW • Jan 27, 2023 11:59 AM
IQST - iQSTEL Reminds Shareholders To Get Their Votes In Before Annual Meeting Next Week On January 31, 2023 • IQST • Jan 26, 2023 9:53 AM
Nextech AR's AI-Powered CAD to Poly Toggle3D Launches Major Technology Advancements • ARWYF • Jan 26, 2023 8:46 AM
UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023 • UCASU • Jan 26, 2023 7:21 AM
Kaya Holdings, Inc. (OTCQB: KAYS) Launches Fifth Dimension Therapeutics™ to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and Address the Growing Multi-Billion Dollar Global Psychedelics Market • KAYS • Jan 25, 2023 10:53 AM